Key Highlights

  • Argenica Therapeutics (ASX: AGN) traded at A$0.20, up 17.65% or A$0.03 at 2:02pm on 17 August 2026.
  • Mesoblast (ASX: MSB) traded at A$2.41, up 9.05% or A$0.20 at 2:58pm on the same day.
  • AGN is preparing for a late-stage acute ischaemic stroke trial for xaranetide, while MSB has completed treatment of 350 patients in its pivotal Phase 3 chronic low back pain trial.

Two ASX-listed healthcare companies recorded sizeable share-price gains on 17 August 2026 as investors responded to developments in their respective clinical programs. Argenica Therapeutics (ASX:AGN) was up 17.65% to A$0.20, while Mesoblast (ASX:MSB) gained 9.05% to A$2.41, at the time of writing on 17 August 2026. Both companies are progressing clinical-stage therapies, although their programs are at different stages of development. Recent market reports also highlighted the clinical milestones behind the respective share-price moves.

Argenica Therapeutics Advances Xaranetide Program

Argenica Therapeutics (ASX:AGN) recorded the larger percentage gain, trading at A$0.20 at 2:02pm, representing an increase of A$0.03.

The company's 24 July quarterly update outlined preparations for a late-stage clinical trial of ARG-007, now known as xaranetide, in moderate to severe acute ischaemic stroke. During the June quarter, Argenica convened a global Stroke Clinical Advisory Committee to review and optimise the proposed clinical trial design.

The planned trial is expected to use a precision-medicine strategy. Argenica previously completed a Phase 2 clinical trial of ARG-007 in acute ischaemic stroke patients across Australian hospitals during 2025.

FDA Testing Completed as Trial Preparation Continues

Argenica reported that three assays requested by the US Food and Drug Administration — hERG, TNK and genotoxicity — had been completed, with the company reporting favourable safety profiles.

The next steps involve finalising the late-stage trial protocol and preparing a comprehensive response to the FDA clinical hold. Argenica intends to seek approval of its Investigational New Drug application before commencing a clinical trial in the United States.

The World Health Organisation has also confirmed xaranetide as the International Nonproprietary Name for ARG-007. The company is additionally examining xaranetide's potential in other neurological conditions after reporting neuroprotective findings in a preclinical concussion study. Argenica's ASX announcements confirm the June completion of the FDA-requested assays and WHO confirmation of the drug's international name.

At 30 June 2026, Argenica had A$6.35 million in cash reserves. The company also said it had secured more than A$4 million in non-dilutive grant and philanthropic funding across its research programs.

Mesoblast Completes Treatment in 350-Patient Phase 3 Trial

Mesoblast (ASX:MSB) was trading at A$2.41, up 9.05%, or A$0.20, at 2:58pm on 17 August.

The company announced that it had completed patient treatment in its pivotal MSB-DR004 Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. A total of 350 patients have been randomised and treated with either rexlemestrocel-L or a sham injection.

The patient count was increased from the original 300 after trial investigators sought to enrol additional participants. The primary endpoint is designed to measure durable pain reduction 12 months after a single intradiscal injection.

Secondary endpoints cover physical function, quality of life and cessation of pain medication, including opioids.

Mid-2027 Readout Becomes the Next Major Milestone

With patient treatment now completed, the program moves into the follow-up period. Mesoblast expects top-line results in mid-calendar 2027, after the final treated patient completes 12 months of follow-up. The company has an agreement with the FDA covering the trial design and the 12-month pain-reduction primary endpoint.

Rexlemestrocel-L also has Regenerative Medicine Advanced Therapy designation from the FDA for chronic low back pain caused by degenerative disc disease. Mesoblast separately markets Ryoncil, its remestemcel-L-rknd product for steroid-refractory acute graft-versus-host disease in paediatric patients.

Different Clinical Milestones Drive Both Stocks

The two companies' updates reflect different stages in their respective development programs. Argenica is focused on regulatory and trial preparations before a proposed late-stage stroke study, while Mesoblast has completed treatment in a pivotal Phase 3 trial and is awaiting the 12-month efficacy assessment.

For Argenica, the immediate development sequence includes finalising the trial protocol, responding to the FDA clinical hold and seeking IND approval. For Mesoblast, the principal upcoming milestone is the Phase 3 readout expected in mid-2027. Neither company's latest announcement establishes the ultimate clinical efficacy or regulatory outcome of its respective program.

Conclusion

Argenica Therapeutics and Mesoblast were among the notable ASX healthcare gainers on 17 August 2026, with AGN rising 17.65% and MSB increasing 9.05% based on the market prices provided. Argenica's move followed progress toward a late-stage acute ischaemic stroke program for xaranetide, including completion of FDA-requested assays, while Mesoblast reached completion of treatment for 350 patients in its pivotal chronic low back pain Phase 3 trial. The two companies now face different development milestones, with Argenica working toward regulatory clearance for its next trial and Mesoblast progressing through patient follow-up ahead of its expected mid-2027 results.